Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$73.38 USD

73.38
341,471

-0.65 (-0.88%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $73.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merit Medical (MMSI) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BDX or MMSI: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BDX vs. MMSI: Which Stock Is the Better Value Option?

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

BDX vs. MMSI: Which Stock Is the Better Value Option?

by Zacks Equity Research

BDX vs. MMSI: Which Stock Is the Better Value Option?

Merit Medical (MMSI) Down 0.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Merit Medical (MMSI) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System

by Zacks Equity Research

Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.

Why Merit Medical (MMSI) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Merit Medical (MMSI) Q4 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the fourth quarter.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Compared to Estimates, Merit Medical (MMSI) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Merit Medical (MMSI) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 5.19% and 1.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Cooper Companies (COO) in Q1 Earnings?

by Zacks Equity Research

Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.

What's in Store for Patterson Companies (PDCO) in Q3 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.

What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) fourth-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.

Stay Ahead of the Game With Merit Medical (MMSI) Q4 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Merit Medical (MMSI), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

The Cooper Companies (COO) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merit Medical (MMSI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Merit Medical (MMSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merit Medical's (MMSI) SCOUT Guidance System Gets FDA Nod

by Zacks Equity Research

Merit Medical's (MMSI) SCOUT MD Surgical Guidance System receives FDA clearance, which aims to boost the treatment of breast cancer by increasing accuracy to target tumor sites.

West Pharmaceutical Services (WST) Beats Q4 Earnings Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 2.81% and 0.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for West Pharmaceutical (WST) in Q4 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) fourth-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

What's in the Cards for Medtronic (MDT) in Q3 Earnings?

by Zacks Equity Research

Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal third-quarter performance.